Ultragenyx Pharmaceutical (RARE) Competitors $30.31 -0.92 (-2.95%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$30.68 +0.37 (+1.20%) As of 09/12/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. RDY, QGEN, BBIO, MRNA, ELAN, VRNA, ROIV, RVMD, GRFS, and ABVXShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Grifols Abivax Ultragenyx Pharmaceutical (NASDAQ:RARE) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Do analysts prefer RARE or RDY? Ultragenyx Pharmaceutical currently has a consensus target price of $81.50, suggesting a potential upside of 168.89%. Dr. Reddy's Laboratories has a consensus target price of $16.95, suggesting a potential upside of 15.70%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Do insiders & institutionals hold more shares of RARE or RDY? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor RARE or RDY? In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Ultragenyx Pharmaceutical and 4 mentions for Dr. Reddy's Laboratories. Ultragenyx Pharmaceutical's average media sentiment score of 1.09 beat Dr. Reddy's Laboratories' score of 0.80 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RARE or RDY? Ultragenyx Pharmaceutical has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Which has better earnings and valuation, RARE or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M5.21-$569.18M-$5.53-5.48Dr. Reddy's Laboratories$3.81B3.21$663M$0.6622.20 Is RARE or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-87.34% -237.48% -37.66% Dr. Reddy's Laboratories 16.99%17.25%11.63% SummaryDr. Reddy's Laboratories beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.01B$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-5.4821.4375.4125.98Price / Sales5.21433.72515.95180.52Price / CashN/A46.6837.5660.44Price / Book10.989.6112.156.29Net Income-$569.18M-$53.29M$3.29B$271.07M7 Day Performance-4.75%0.13%0.74%3.87%1 Month Performance4.48%5.55%5.00%5.49%1 Year Performance-48.40%10.44%62.55%25.86% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.4674 of 5 stars$30.31-2.9%$81.50+168.9%-48.4%$3.01B$560.23M-5.481,294Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.2718 of 5 stars$14.27-0.5%$16.95+18.8%-8.9%$11.91B$334.26B21.6127,811Positive NewsQGENQiagen4.4722 of 5 stars$47.62+0.1%$49.69+4.4%+0.5%$10.58B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.445 of 5 stars$54.29+1.7%$63.35+16.7%+95.6%$10.38B$221.90M-13.27400Analyst ForecastMRNAModerna4.4674 of 5 stars$24.83-1.2%$42.88+72.7%-65.6%$9.66B$3.24B-3.305,800News CoverageELANElanco Animal Health2.6248 of 5 stars$19.02+3.2%$17.33-8.9%+28.0%$9.45B$4.44B22.129,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.3158 of 5 stars$106.300.0%$109.00+2.5%+257.4%$9.19B$42.28M-107.3730Positive NewsROIVRoivant Sciences3.1434 of 5 stars$12.91-0.1%$16.38+26.8%+17.9%$8.82B$29.05M-18.44860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.1933 of 5 stars$41.06+1.4%$72.00+75.4%+6.5%$7.68B$11.58M-9.12250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.9836 of 5 stars$10.11-0.2%$10.30+1.9%+6.7%$6.95B$7.81B8.6423,822News CoveragePositive NewsABVXAbivax2.5661 of 5 stars$90.00+2.2%$92.33+2.6%+616.8%$6.80BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownHigh Trading Volume Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
